Dong-A Pharmaceutical Co.,Ltd

donga.co.kr

Established in 1932, Dong-A Pharm. has been the leading pharmaceutical company in South Korea with its business focus in developing, manufacturing and distributing innovative products for the healthier life of our society. Headquartered in South Korea, Dong-A Pharm. employs over 2,300 people worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

SOPHIA GENETICS LAUNCHES NEW DEEP LEARNING CAPABILITIES TO SUPPORT THE DETECTION OF HOMOLOGOUS RECOMBINATION DEFICIENCIES

SOPHiA GENETICS | March 08, 2022

news image

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. HRD is caused by a cell's impaired ability to repair ...

Read More

REVITOPE, JUNSHI BIOSCIENCES ENTER INTO RESEARCH COLLABORATION TO DEVELOP FIRST-IN-CLASS DUAL-ANTIGEN TARGETING CANCER THERAPIES

Revitope Oncology | July 14, 2020

news image

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a stra...

Read More

Cell and Gene Therapy

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

news image

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More

Industrial Impact

N-LOREM FOUNDATION PARTNERS WITH ARGONAUT TO MANUFACTURE ASO MEDICINES FOR PATIENTS WITH NANO-RARE DISEASES

Argonaut Manufacturing Services | February 02, 2022

news image

Argonaut Manufacturing Services, a leading contract manufacturing organization, and n-Lorem, a nonprofit foundation, today announced a new partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide medicines developed for nano-rare disease patients for free, for life. “Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personal...

Read More
news image

Cell and Gene Therapy

SOPHIA GENETICS LAUNCHES NEW DEEP LEARNING CAPABILITIES TO SUPPORT THE DETECTION OF HOMOLOGOUS RECOMBINATION DEFICIENCIES

SOPHiA GENETICS | March 08, 2022

SOPHiA GENETICS (Nasdaq: SOPH), a leader in Data-Driven Medicine, announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples. HRD is caused by a cell's impaired ability to repair ...

Read More
news image

REVITOPE, JUNSHI BIOSCIENCES ENTER INTO RESEARCH COLLABORATION TO DEVELOP FIRST-IN-CLASS DUAL-ANTIGEN TARGETING CANCER THERAPIES

Revitope Oncology | July 14, 2020

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a stra...

Read More
news image

Cell and Gene Therapy

ADICET BIO REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Adicet Bio, Inc. | September 06, 2022

Adicet Bio, Inc. a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, today announced it granted inducement awards on August 31, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to five individuals hired by Adicet in August 2022. The employees received, in the aggregate, non-qualified stock options to purchase 114,200 shares of Adicet’s common stock with an exercise pric...

Read More
news image

Industrial Impact

N-LOREM FOUNDATION PARTNERS WITH ARGONAUT TO MANUFACTURE ASO MEDICINES FOR PATIENTS WITH NANO-RARE DISEASES

Argonaut Manufacturing Services | February 02, 2022

Argonaut Manufacturing Services, a leading contract manufacturing organization, and n-Lorem, a nonprofit foundation, today announced a new partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide medicines developed for nano-rare disease patients for free, for life. “Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personal...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us